Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Functions and Clinical Applications of Extracellular Vesicles in T H 2 Cell-Mediated Airway Inflammatory Diseases: A Review

Cheon J., Kim B., Lee J., Shin J., Kim TH.

Narrative Review, published in Int J Mol Sci (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Int J Mol Sci (2024)
Reported sample size
—
Source database
Europe PMC
PMID
39273399
PMCID
PMC11394744
DOI
10.3390/ijms25179455
Citations
4

Abstract (original English)

Type 2 airway inflammation (T2AI), driven by type 2 innate lymphoid and CD4 + T helper 2 cells, leads to various diseases and conditions, such as chronic rhinosinusitis with nasal polyps, allergic rhinitis, and asthma. Emerging evidence suggests the involvement of extracellular vesicles (EVs) in these diseases. In this review, we describe the immunological T2AI pathogenic mechanisms, outline EV characteristics, and highlight their applications in the diagnosis and treatment of T2AI. An extensive literature search was conducted using appropriate strategies to identify relevant articles from various online databases. EVs in various biological samples showed disease-specific characteristics for chronic rhinosinusitis with nasal polyps, allergic rhinitis, and asthma, with some demonstrating therapeutic effects against these conditions. However, most studies have been limited to in vitro and animal models, highlighting the need for further clinical research on the diagnostic and therapeutic applications of EVs.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Th2 CellsAnimalsHumansAsthmaSinusitisRhinitisNasal PolypsInflammationRhinitis, AllergicExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.